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Objective: To clarify the impact of mild post-procedural aortic regurgita-
tion (post-AR) on clinical outcomes.
Background: Post-procedural aortic regurgitation (post-AR) is known to
be associated with poor short-mid term outcome after transcatheter aortic
valve implantation (TAVI).
Methods: We compared clinical outcomes in 400 consecutive TAVI recip-
ients according to post-AR grade: none (group 1=74.8%), mild (group
2=22.2%) or moderate to severe (group 3=3.0%).
Results: The mean age was similar in the 3 groups (83.4±6.1years) as well
as logistic EuroSCORE (22.5±11.4, 24.5±11.6 and 21.5±9.4%, p=0.28) and
annulus size (22.0±1.8, 22.2±2.1 and 22.5±2.1 mm, p=0.53).
The Edwards valve was the most frequently used in group 1 compared to
group 2 and 3 (89.3, 78.7 and 83.3%, p=0.03) and the implanted valve size
was similar in all groups (25.6±2.0, 25.4±2.2 and 25.5±2.2 mm respectively,
p=0.69). Post-dilatation was required more frequently in group 3 (4.7, 24.1
and 50.0% respectively, p<0.01). Post-procedural increase in mitral regurgita-
tion was in line with the post-AR grade (0.78±0.73, 1.22±0.80 and 1.89±0.78,
respectively, p<0.01).
Despite the absence of difference in 30-day mortality, longer-term outcome
showed patients with mild AR had a significantly worse outcome compared to
none (log-rank p<0.01) and better than moderate to severe (p=0.04), regard-
less of TAVI type and left ventricular function.
Post-AR was also identified as an independent predictor for mid-long term
mortality (HR1.68, 95%CI:1.21-1.44, p<0.01).
Conclusion: Mild post-AR after TAVI is associated with worse outcome
compared to none to trivial. Cautious valve selection and post-dilatation when
required to avoid mild post-AR might contribute to improved clinical outcome
after TAVI.
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Background and objective: Bleeding post-PCI is associated with
increased in-hospital mortality and adverse outcomes. Data regarding the
determinants and outcomes of bleeding after transcatheter aortic valve implan-
tation (TAVI) are limited. We assessed the incidence, predictors and clinical
impact of bleeding after TAVI in patients from a single center registry.
Methods: We included 250 consecutive patients implanted in our center
between May 2006 and October 2011. All procedures were performed using
the balloon expandable Edwards SAPIEN and SAPIEN XT valves, via trans-
femoral (TF) and transapical (TA) approach. Introducers of 22 and 24 F or
surgical cutdown were used for TF access when implanting the SAPIEN
valve, while SAPIEN XT valve was implanted using 18 and 19F sheaths and
percutaneous closure. The Ascendra 1, 28F and 2, 26F systems were used for
TA access. Dual antiplatelet therapy was administered preprocedurally in TF
cases, aspirin only in TA cases, with 70 UI/kg of unfractionated heparin after
sheath insertion. Life-threatening (LTB), major, minor bleeding and other
complications were defined using VARC criteria.
Results: TAVI was performed via TF access in 190 (76%) cases, and the
SAPIEN XT model was used in 123 (49.2%) cases. Bleeding after TAVI was
observed in 68 (27.2%) patients as follows: LTB in 33 (13.2%), major
bleeding in 23 (9.2%) and minor bleeding in 12 (4.8%). After multivariate
analysis, only TA access was an independent predictor of LTB (OR 3.35, 95%
CI: 1.52 – 7.38, p<0.003). Patients presenting LTB post-TAVI had a higher
30-day mortality: 33.3% vs. 3.7%, p<0.001 and 1-year mortality: 46% vs.
82%, p<0.001. LTB was an independent predictive factor for 30-day (OR
6.98, 95% CI: 1.93 – 25.1, p=0.003) and 1-year mortality (HR 2.18, 95% CI:
1.11 – 4.28, p=0.024).
Conclusion: Bleeding represents a frequent complication of TAVI, being
observed in over 25% of cases in this single center registry. It is associated
with higher 30-day and 1 year mortality.
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Background: Transcatheter aortic valve implantation (TAVI) has become
a recognized alternative to conventional surgery in high-risk patients with
severe symptomatic aortic stenosis. However, little is known about the long-
term durability of the prosthesis as assessed by periodic transthoracic echo-
cardiography (TTE). We aim to evaluate aortic valve hemodynamics by TTE
performed after TAVI using Edwards Sapien/Sapien XT bioprosthesis.
Methods: All consecutive patients implanted between March 2005 and
January 2012 were included in a prospective registry. TTE data were collected
before TAVI, within 7 days, at 6 months and yearly after the procedure. Dop-
pler interrogation was used for peak, mean pressure gradient and effective ori-
fice area (EOA) using the continuity equation. Aortic regurgitation (AR) and
ejection fraction (EF) were assessed.
Results: Two hundred and sixty one patients underwent successful TAVI
implantation and were included in the registry (table). Left ventricular ejection
fraction (LVEF) was improved early after TAVI procedure. Both Peak and
mean pressure gradient significantly decreased after TAVI while EOA
increased. No aortic regurgitation >grade 2 was found 3 and 4 years after
TAVI. Four-year TTE follow-up did not demonstrate any significant change
in peak pressure gradient, mean pressure gradient, EOA or occurrence of
severe aortic regurgitation compared to 7-day post-operative. All parameters
except LVEF remained significantly improved at 4-year compared to pre-
TAVI examination.
Conclusion: Our study demonstrates the excellent hemodynamic perfor-
mance of the Edwards Sapien/Sapien XT aortic bioprosthesis 4-year after tran-
scatheter implantation offering promising information on valve durability.
Table – TTE parameters
b of 
patients
EF (%) EDV 
(ml)
Peak 
pressure 
grandient 
(mmHg)
Mean 
pressure 
gradient 
(mmHg)
EOA 
(cm2)
AR >
 grade 2
(nb of 
patients)
Before 
TAVI
261 55±16 106±40 70±26 46±25 0.66±0.15 9
7 days 261 60±13* 101±43 19±7* 10±4* 1.78±0.24* 12*
6 months 140 61±11* 99±54 18±6* 10±3* 1.77±0.26* 4*
1 year 122 60±12* 103±44 18±7* 10±4* 1.77±0.29* 1*
2 years 56 61±11* 101±51 19±8* 10±5* 1.68±0.25*µ 1*
3 years 25 62±8* 106±25 18±5* 10±3* 1.79±0.30* 0
4 years 9 55±16 123±50 18±5* 10±3* 1.75±0.20* 0
EDV: end diastolic volume. *: p<0.05 vs. before TAVI. µ: p<0.05 vs. 7 days after 
TAVI
